By Eli Flesch (Sept. 17, 2021, 7:11 p.m. EDT) – US Specialty Insurance Co. asked the Ninth Ward on Friday to confirm its finding that a California pharmaceutical company was not eligible for the costs incurred under it from an investigation into the company’s opioid drugs and marketing practices.
The insurer said a merchandise and product exclusion in its policy with San Diego-based drug maker Sentynl Therapeutics was correctly interpreted to denote $ 2.4 million coverage the drug company spent responding to subpoenas Getting information on marketing levorphanol, one of its prescription opioids, essentially rules out drugs.
This is because the policy clearly excluded coverage for damage from damage that …
Stay ahead of the curve
In the legal profession, information is the key to success. You need to know what is happening to customers, competitors, practice areas and industries. Law360 offers the intelligence you need to stay an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, type of lawsuit, etc.)
Access to attached documents such as Briefs, petitions, complaints, decisions, motions, etc.
Create custom notifications for specific article and case topics and much more!